Good news about Alzheimer’s
Summary
This episode explores the history of Alzheimer’s research, highlighting how a retracted study based on doctored images fueled decades of failed drug trials targeting amyloid plaques. Host Dylan Scott then shares good news, detailing the FDA approval of two new anti-amyloid drugs that slow cognitive decline and the rise of blood tests for early detection. The discussion also covers emerging treatments targeting tau proteins and vascular health, as well as intriguing but unverified surgical procedures in China that claim to reverse symptoms.
Topics discussed
Introduction: The terror of losing identity to Alzheimer's
Sponsor: Mint Mobile and Anthropic
The scale of Alzheimer's vs. cancer treatments
History: Alois Alzheimer and the rise of the disease
The Amyloid Cascade Hypothesis explained
Failed early attempts to remove plaques
The Aβ*56 protein and the Minnesota experiment
The scandal: Doctored images and retracted study
Charles Pillar's book and the cost of the fraud
Sponsor: Chime fee-free banking
Sponsor: Anthropic and AI public benefit
Good news: New treatments and early detection tools
Leqembi and Donanemab: The first FDA-approved drugs
Beyond amyloid: Tau, inflammation, and vascular health
GLP-1 drugs and potential Alzheimer's prevention
The mystery of Chinese reversal surgery videos
Surgical mechanics, skepticism, and the goal of restoring identity
Credits and Sponsor: Stitch Fix
Listen ad-free on Castria